Latest news with #tenderoffer
Globe and Mail
10-07-2025
- Business
- Globe and Mail
BlackRock Technology and Private Equity Term Trust (BTX) Announces Final Results of Tender Offer
BlackRock Technology and Private Equity Term Trust (the 'Fund') announced today the final results of the Fund's tender offer (the 'Tender Offer') for up to 50% of its outstanding common shares (the 'Shares'), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850 7.4924 *Equal to 99.5% of the Fund's net asset value per Share as of the close of regular trading on the New York Stock Exchange on July 9, 2025 (the business day immediately following the expiration date of the Tender Offer). Important Notice This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund's common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission ('SEC') as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at or by directing such requests to the Fund. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit Availability of Fund Updates BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the 'Closed-end Funds' section of as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock's website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock's website in this release. Forward-Looking Statements This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund's or BlackRock's future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as 'trend,' 'potential,' 'opportunity,' 'pipeline,' 'believe,' 'comfortable,' 'expect,' 'anticipate,' 'current,' 'intention,' 'estimate,' 'position,' 'assume,' 'outlook,' 'continue,' 'remain,' 'maintain,' 'sustain,' 'seek,' 'achieve,' and similar expressions, or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' 'may' or similar expressions. BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund's net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock's ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions. Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC's website at and on BlackRock's website at and may discuss these or other factors that affect the Fund. The information contained on BlackRock's website is not a part of this press release.
Yahoo
10-07-2025
- Business
- Yahoo
BlackRock Technology and Private Equity Term Trust (BTX) Announces Final Results of Tender Offer
NEW YORK, July 10, 2025--(BUSINESS WIRE)--BlackRock Technology and Private Equity Term Trust (the "Fund") announced today the final results of the Fund's tender offer (the "Tender Offer") for up to 50% of its outstanding common shares (the "Shares"), which expired on July 8, 2025. The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made approximately five business days after the pricing date (anticipated to be July 16, 2025). The final results of the Tender Offer are provided in the table below: Fund Name Ticker CUSIP Number ofSharesOffered for Repurchase Number ofTendered Sharesto be Purchased PurchasePrice* BlackRock Technology and Private Equity Term Trust BTX 09260Q108 106,669,074 96,627,850 7.4924 *Equal to 99.5% of the Fund's net asset value per Share as of the close of regular trading on the New York Stock Exchange on July 9, 2025 (the business day immediately following the expiration date of the Tender Offer). Important Notice This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund's common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission ("SEC") as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at or by directing such requests to the Fund. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit Availability of Fund Updates BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the "Closed-end Funds" section of as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock's website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock's website in this release. Forward-Looking Statements This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund's or BlackRock's future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as "trend," "potential," "opportunity," "pipeline," "believe," "comfortable," "expect," "anticipate," "current," "intention," "estimate," "position," "assume," "outlook," "continue," "remain," "maintain," "sustain," "seek," "achieve," and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may" or similar expressions. BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund's net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock's ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions. Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC's website at and on BlackRock's website at and may discuss these or other factors that affect the Fund. The information contained on BlackRock's website is not a part of this press release. View source version on Contacts 1-800-882-0052 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-07-2025
- Business
- Yahoo
BlackRock MuniVest Fund, Inc. (MVF) Announces Tender Offer in Conjunction with Results of the Quarterly Measurement Period of its Discount Management Program
NEW YORK, July 01, 2025--(BUSINESS WIRE)--BlackRock MuniVest Fund, Inc. (MVF) announced today the results of the Quarterly Measurement Period (as defined below) under its previously announced discount management program (the "Program"). MVF (the "Fund") also announced the dates of its tender offer as a result of the occurrence of a Trigger Event (as defined below) at the end of the Quarterly Measurement Period with respect to the Fund. The Program is part of the Fund's ongoing effort to manage its discount, enhance long-term shareholder value and provide liquidity to the market for its common shareholders. There can be no assurances as to the effect that the Program will have on the market for the Fund's shares or the discount at which the Fund's shares may trade relative to its NAV. As previously announced, under the Program, the Fund intends to offer to repurchase a portion of its outstanding common shares based on 3-month measurement periods (each a "Measurement Period") if the Fund's common shares trade at an average daily discount to net asset value ("NAV") of greater than 7.50% during a Measurement Period (a "Trigger Event"). The Fund's Measurement Period commenced on April 1, 2025 and ended on June 30, 2025 (the "Quarterly Measurement Period"). The average daily discount to NAV for the Fund during the Quarterly Measurement Period is summarized below. Press Release: BlackRock MuniVest Fund, Inc. (MVF) Announces Adoption of Discount Management Program. Quarterly Measurement Period Discount Results for the Fund Fund Name Ticker Average Daily Discount forthe Measurement Periodended June 30, 2025 BlackRock MuniVest Fund, Inc. MVF -7.60% The Fund's Boards of Directors (the "Board") determined that if a Trigger Event occurred during the Quarterly Measurement Period, the Fund would offer to repurchase a portion of its outstanding common shares by conducting a tender offer for 2.5% of its outstanding common shares at a price equal to 98% of the Fund's NAV per share as determined as of the close of the regular trading session of the New York Stock Exchange ("NYSE") on the next day the NAV is calculated after the expiration date of the tender offer or, if the offer is extended, on the next day the NAV is calculated after the day to which the offer is extended. As a result of the occurrence of a Trigger Event during the Quarterly Measurement Period with respect to the Fund, the Board has authorized the Fund's tender offer with the anticipated commencement and expiration dates outlined below. Event MVF Tender Offer Commencement Date Tuesday, July 15, 2025 Tender Offer Expiration Date and Time Friday, August 15, 2025 at 5:00 p.m. Eastern Time, unless otherwise extended If more than 2.5% of the Fund's outstanding common shares are tendered, the Fund will purchase its shares from tendering shareholders on a pro rata basis at a price equal to 98% of the Fund's NAV per share as determined as of the close of the regular trading session of the NYSE on the next day the NAV is calculated after the expiration date of the tender offer (or, if the offer is extended, on the next day the NAV is calculated after the day to which the offer is extended). Accordingly, there is no assurance that the Fund will purchase all of a shareholder's common shares tendered in the tender offer. Payments for shares tendered and accepted are expected to be made approximately five business days after the expiration date. The terms and conditions of the Fund's tender offer will be set forth in an Offer to Purchase, a related Letter of Transmittal, and related documents, which will be distributed to the Fund's common shareholders. As soon as its tender offer commences, the Fund will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the "SEC"), which will include an Offer to Purchase and related Letter of Transmittal. IMPORTANT NOTICE This press release is for informational purposes only and is not a recommendation, an offer to purchase or a solicitation of an offer to sell any securities of the Fund and the above statements are not intended to constitute an offer to participate in any tender offer. Any offer to purchase Fund common shares will be made pursuant to an offer on Schedule TO. COMMON SHAREHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS, INCLUDING THE OFFER TO PURCHASE AND ANY SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE TENDER OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY ARE FILED AND BECOME AVAILABLE, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF COMMON SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. Common shareholders may obtain a free copy of any of these statements and other documents filed with the SEC at the website maintained by the SEC at or by directing such requests to the Fund. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit Availability of Fund Updates BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the "Closed-end Funds" section of as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock's website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock's website in this release. Forward-Looking Statements This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund's or BlackRock's future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as "trend," "potential," "opportunity," "pipeline," "believe," "comfortable," "expect," "anticipate," "current," "intention," "estimate," "position," "assume," "outlook," "continue," "remain," "maintain," "sustain," "seek," "achieve," and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may" or similar expressions. BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance. With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund's net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock's ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions. Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC's website at and on BlackRock's website at and may discuss these or other factors that affect the Fund. The information contained on BlackRock's website is not a part of this press release. View source version on Contacts 1-800-882-0052 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
26-06-2025
- Business
- Globe and Mail
Transom Capital Commences Friendly Tender Offer for All Outstanding Common Shares of SigmaTron International at $3.02 Per Share
LOS ANGELES, June 26, 2025 (GLOBE NEWSWIRE) -- Transom Capital Group, LLC ('Transom'), an operationally focused middle-market private equity firm, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of SigmaTron International, Inc. (NASDAQ: SGMA) (the 'Company' or 'SigmaTron'), an electronic manufacturing services company, at a price of $3.02 per share in cash. The tender offer is being made in connection with the previously announced Agreement and Plan of Merger, dated May 20, 2025 (as amended or supplemented from time to time, the 'Merger Agreement'). 'We are excited to launch our tender offer today and deeply value the unanimous support of SigmaTron's Board of Directors, which reflects their confidence in this transaction,' said Russ Roenick, Co-Founder and Managing Partner of Transom. 'This offer provides certainty of value and immediate significant liquidity to SigmaTron stockholders, while underscoring our commitment to the Company's long-term success. Upon successful completion of the tender offer, we look forward to partnering with SigmaTron to build on its legacy and drive its next chapter of growth.' Transom Offer Unanimously Recommended by SigmaTron Board of Directors The SigmaTron Board of Directors (the 'SigmaTron Board') unanimously determined that the offer and the merger are advisable and in the best interest of SigmaTron and its stockholders and recommends the stockholders tender their shares to Transom. The SigmaTron Board, with the assistance of its management team and advisors, engaged in a comprehensive review of a range of financial and strategic alternatives and engaged with over thirty parties to determine interest in a transaction. The SigmaTron Board also reviewed a proposal submitted by a third party following the announcement of the Merger Agreement. The third party subsequently communicated to the Company that it was no longer pursuing a transaction and withdrew its proposal. Cash Consideration Provides Immediate Liquidity and Certainty of Value The SigmaTron Board took into account various factors, including, among other things, the potential risks related to SigmaTron's significant level of indebtedness and the terms of such indebtedness, in its determination, as described further in SigmaTron's Schedule 14D-9 (as defined below). The SigmaTron Board believed the certainty of value provided by the $3.02 cash offer and the timing in which the transaction could be consummated, among other things, was in the best interests of SigmaTron's stockholders. Tender Offer Details On June 26, 2025, Transom filed with the U.S. Securities and Exchange Commission ('SEC') a tender offer statement on Schedule TO, including an offer to purchase and letter of transmittal (the 'Schedule TO'), which sets forth the terms of the tender offer. Additionally, SigmaTron filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the 'Schedule 14D-9') that includes the recommendation of the SigmaTron Board that SigmaTron stockholders accept the tender offer and tender their shares. The tender offer is scheduled to expire at one minute after 11:59 p.m., Eastern Time, on July 24, 2025, unless extended in accordance with the terms of the tender offer and Merger Agreement. Consummation of the tender offer is subject to customary terms and conditions, including the tender of a number of shares of common stock of SigmaTron which represents at least a majority of the voting power of SigmaTron and the satisfaction of other customary closing conditions. Following the successful closing of the tender offer, Transom will acquire any shares of SigmaTron that are not tendered in the tender offer through a second-step merger for the same consideration as paid in the tender offer. The complete terms and conditions of the tender offer are set forth in the Schedule TO, including the offer to purchase and a letter of transmittal, which have been filed with the SEC and are being mailed to SigmaTron's stockholders together with the Schedule 14D-9. A copy of these documents may be obtained at the website maintained by the SEC at D.F. King & Co., Inc. is acting as information agent for Transom in the offer. Equiniti Trust Company, LLC is acting as the depositary and paying agent in the offer. Requests for documents and questions by stockholders relating to the offer may be directed to D.F. King & Co., Inc. by telephone at (877) 732-3613 (toll-free). Additional Information and Where to Find It This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of the Company. It is also not a substitute for the tender offer materials that Transom Axis AcquireCo, LLC ('Parent') and Transom Axis MergerSub, Inc., an affiliate of Transom ('Merger Sub') have filed and may in the future file with the SEC. Parent and Merger Sub have filed tender offer materials on Schedule TO with the SEC, and the Company has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AND ANY OTHER RELEVANT DOCUMENTS FILED BY THE COMPANY, PARENT OR MERGER SUB CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY THE COMPANY'S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Free copies of these materials are available to the Company's stockholders by visiting the Company's website ( In addition, these materials (and all other documents filed by the Company, Parent and Merger Sub with the SEC) are available at no charge on the SEC's website ( The information contained in, or that can be accessed through, the Company's or Transom's respective websites is not a part of this communication or incorporated by reference herein. About Transom Capital Group Transom is a leading operationally-focused private equity firm that thrives in complexity, specializing in identifying and unlocking value in the middle market. Founded in 2008 and headquartered in Los Angeles, Transom has established a strong track record across various economic cycles by employing a time-tested, operationally intensive strategy to drive transformative outcomes. Transom's expertise spans corporate carve-outs, lender-owned businesses, undervalued public companies, and other complex situations requiring speed, flexibility, and precision. Supported by a large in-house operations team, Transom delivers tailored solutions backed with functional expertise to help companies unlock their full potential. Transom's sector-flexible approach is grounded in pattern recognition, value creation, and disciplined execution. The firm provides not only capital, but also the tools, insights, and operational capabilities necessary to accelerate performance and create long-term value. For more information, visit Media Contacts
Yahoo
25-06-2025
- Business
- Yahoo
Novartis announces expiration of Regulus Therapeutics tender offer
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the 'Offer') by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ('Purchaser'), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the 'Shares'), of Regulus Therapeutics Inc. ('Regulus'), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a 'CVR') per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025 (the 'Expiration Time'). Computershare Trust Company, N.A., the depositary for the Offer, has advised that, as of the Expiration Time, approximately 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the Expiration Time. The parties expect the transaction to close on June 25, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the Offer. Additional Information This press release is neither an offer to purchase nor a solicitation of an offer to sell any Shares or any other securities. At the time the tender offer described in this press release was commenced, Novartis and Purchaser filed a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the U.S. Securities and Exchange Commission (the 'SEC'), and Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, in each case with respect to the tender offer. An offer to purchase the Shares is only being made pursuant to the offer to purchase, the letter of transmittal and related offer documents filed as a part of the Schedule TO. Those materials and all other documents filed by, or caused to be filed by, Novartis, Purchaser and Regulus with the SEC are available at no charge on the SEC's website at or by directing such requests to the information agent for the offer, which is named in the tender offer statement. The offer to purchase and related materials also may be obtained for free under the 'Investors – Financial Data' section of Novartis website at The solicitation/recommendation statement also may be obtained for free under the 'Investors' section of Regulus' website at In addition, Regulus files annual, quarterly and current reports and other information, and Novartis files annual reports and other information with the SEC, which are also available to the public at no charge at Disclaimer This press release contains statements that are not statements of historical fact, or 'forward-looking statements,' including with respect to Novartis' proposed acquisition of Regulus. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for farabursen, regarding the proposed acquisition of Regulus and the expected timetable for completing the proposed acquisition, the benefits sought to be achieved in the proposed acquisition, or regarding potential future revenues from farabursen. You should not place undue reliance on these statements. Such forward-looking statements are based on Novartis' current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that farabursen clinical trials will be successful, that farabursen will be submitted for marketing approval or approved for sale or, if approved, receive approval for any additional indications or labeling, in any market, or at any particular time, nor can there be any guarantee that, if approved, farabursen will be commercially successful in the future. Neither can there be any guarantee that the conditions to the closing of the proposed acquisition will be satisfied on the expected timetable or at all or that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all. In particular, expectations regarding farabursen or the transaction described in this press release could be affected by, among other things, the timing of the offer and the satisfaction of customary closing conditions, including the receipt of regulatory approvals on acceptable terms or at all; the risk that competing offers or acquisition proposals will be made; uncertainty as to whether the milestone associated with the CVR will be achieved and that holders of CVRs will receive payments in respect thereof; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Novartis and/or Regulus' businesses, including their relationships with employees, business partners or governmental entities; the risk that the offer or the merger may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; a diversion of management's attention from ongoing business operations and opportunities as a result of the offer, the merger or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate and currency exchange rate fluctuations; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's and Regulus' filings and reports with the SEC, including Novartis AG's Annual Report on Form 20-F for the year ended December 31, 2024, Regulus' Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form10-Q for the quarter ended March 31, 2025 and any subsequent filings made by either party with the SEC, available on the SEC's website at Novartis is providing the information in this press release as of this date and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except to the extent required by law. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
